| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Levonorgestrel Intrauterine System |
| Brand | Levosert® |
| Indication | For contraception and for the treatment of heavy menstrual bleeding. |
| Assessment Process | |
| Rapid review commissioned | 28/08/2019 |
| Rapid review completed | 23/10/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that levonorgestrel-IUS (Levosert®) be considered for reimbursement. |